Fresenius USA Manufacturing, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SAfety of Regional Citrate Anticoagulation (SARCA Study)

Phase 3

Recruiting

Conditions: Acute Kidney Injury
ESRD

Interventions: Combination Product: Dialysis

First Posted Date: 2022-04-21

Last Posted Date: 2024-07-23

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 50

Registration Number: NCT05339139

Locations: 🇺🇸
John L. McClellan Memorial Veterans' Hospital, Little Rock, Arkansas, United States
🇺🇸
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 3 locations

Fresenius Noninvasive Blood Pressure Validation

Not Applicable

Completed

Conditions: Blood Pressure

First Posted Date: 2020-10-05

Last Posted Date: 2021-02-02

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 159

Registration Number: NCT04573595

Locations: 🇺🇸
Clinimark, Site ID#001, Louisville, Colorado, United States

Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™

Not Applicable

Completed

Conditions: Chronic Kidney Diseases
Patient Requiring Heparin Free Dialysis Treatments

Interventions: Device: Dialyzer with Endexo

First Posted Date: 2020-08-13

Last Posted Date: 2022-03-04

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 16

Registration Number: NCT04511338

Locations: 🇺🇸
Fresenius Kidney Care Craven County Dialysis Center, New Bern, North Carolina, United States
🇺🇸
New Bern Dialysis Unit, New Bern, North Carolina, United States

Clinical Study to Assess the Performance of the Dialyzer With Endexo™

Not Applicable

Completed

Conditions: Kidney Failure, Chronic

Interventions: Device: Optiflux and Dialyzer with Endexo

First Posted Date: 2018-05-25

Last Posted Date: 2020-11-27

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 23

Registration Number: NCT03536663

Locations: 🇺🇸
California Institute of Renal Research, San Diego, California, United States
🇺🇸
Balboa Nephrology Med Group, Chula Vista, California, United States
🇺🇸
Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V, Wichita, Kansas, United States

Acid-Base Composition With Use of hemoDialysates

Not Applicable

Completed

Conditions: End Stage Renal Disease

First Posted Date: 2015-01-08

Last Posted Date: 2017-03-09

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 11

Registration Number: NCT02334267

Locations: 🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research, Knoxville, Tennessee, United States

Care Transitions in Renal Disease Patients

Conditions: Renal Disease

First Posted Date: 2013-04-30

Last Posted Date: 2013-04-30

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 3300

Registration Number: NCT01842776

Locations: 🇺🇸
Fresenius, Franklin, Tennessee, United States

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

Phase 4

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Calcium acetate oral solution (COS)
Drug: Sevelamer carbonate

First Posted Date: 2011-09-02

Last Posted Date: 2016-01-14

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 38

Registration Number: NCT01427907

Locations: 🇺🇸
Irving Place Dialysis Center, New York, New York, United States
🇺🇸
North Haven Dialysis, North Haven, Connecticut, United States
🇺🇸
Upper Manhattan Dialysis Clinic (UMDC), New York, New York, United States

and more 1 locations

Phosphate Kinetic Modeling 2

Phase 4

Completed

Conditions: Hyperphosphatemia
ESRD

Interventions: Other: PKM Algorithm

First Posted Date: 2010-12-03

Last Posted Date: 2014-08-18

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 81

Registration Number: NCT01252771

Locations: 🇺🇸
Renal Research Insitutue, New York, New York, United States

A Safety Study of Pentoxifylline for the Treatment of Anemia

Phase 2

Terminated

Conditions: End Stage Renal Disease

Interventions: Drug: Erythropoietin
Drug: Pentoxifylline

First Posted Date: 2010-04-13

Last Posted Date: 2012-03-28

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 48

Registration Number: NCT01102218

Locations: 🇺🇸
Fresenius Medical Care North America, Tyler, Texas, United States

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

Not Applicable

Conditions: Anemia
Mortality

Interventions: Other: Early anemia diagnosis and treatment
Other: No change from normal routine

First Posted Date: 2009-11-20

Last Posted Date: 2010-04-02

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 1500

Registration Number: NCT01017627

Locations: 🇺🇸
Yokna River, Oxford, Mississippi, United States
🇺🇸
West Nashville, West Nashville, Tennessee, United States
🇺🇸
Fresenius Medical Services, Brentwood, Tennessee, United States

and more 39 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy